Dawn M. Dawson, M.D.Assistant Professor
11100 Euclid Ave.
Cleveland, OH 44106
phone: (216) 368-5912
Dr. Dawn Dawson received her M.D. from Eastern Virginia Medical School in 1989. She spent the next few years in residency and fellowship in Anatomic and Clinical Pathology at the Cleveland Clinic Foundation. She was granted Board Certification in 1996. From 1998 until 2000, Dr. Dawson was a fellow in Translation Research in the Oncology Training Program. Currently, she is an Assistant Professor at Case's Institute of Pathology.
Growth factor/receptor cell signaling in early carcinogenesis models, in particular, members of the EGF receptor family active in colon cancer.
Development of tissue-based micro-diagnostic methods for testing efficacy of chemotherapeutic agents targeting activated cell signaling proteins.
Dawson DM , Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, Resnick MI, Kursh ED, Pretlow TP, Pretlow TG. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 90:519-523, 1998.
Venkateswarlu S, Dawson DM, St. Clair P, Gupta A, Willson JKV, Brattain MG. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 21:78-86, 2002.
Markowitz SD , Dawson DM, Willis JE, Willson JKV. Focus on colon cancer. Cancer Cell 1:233-236, 2002.
Brunschwig EB, Wilson K, Mack D, Dawson DM, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbaugh JD, Willis J, Platzer P, Markowitz S. PMEPA1, a transforming growth factor-beta- induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res 63:1568-1575, 2003.
Black JD, Brattain MG, Krishnamurthi S, Dawson DM, Willson JKV. ErbB family targeting. Curr Opin Investig Drugs 4:1451-1454, 2003.
Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JKV, Luo G, Hensold J, Tai H-H, Wilson K, Markowitz S. 15-hydroxyprostaglandin dehydrogenase, a cyclooxygenase- 2 oncogene antagonist, is a TGF- b -induced suppressor of gastrointestinal cancers. Proc Natl Acad Sci U S A . 101(50):17468-73, 2004.
Chen W-D, Skoletsky J, Han J, Olso J, Myeroff L, Platzer P, Sah J, Lu S, Dawson D, Willis J, Pretlow T, Lutterbaugh J, Kasturi L, Willson JKV, Shuber A, Markowitz SD. Detection in fecal DNA of colon cancer specific methylation of the non-expressed vimentin gene. JNCI (in press, 2005).